<span item_type="fundamental" item_id="fcd647b01f29608b37cabb4bbb74a0e9" counter_id="ST/US/BTMD" env="prod"></span><span item_type="announcement" item_id="579536398043454721" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 47.96 M, beating the estimate of USD 47.76 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.22, beating the estimate of USD 0.0467.</p><p>EBIT: As of FY2025 Q3, the actual value is USD 11 M.</p><p></p><h3>Revenue</h3><ul><li>Total revenue for Q3 2025 was $48.0 million, a decrease of 6.7% from $51.4 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li><li>Procedure revenue declined by 10.4%, partially offset by an 8.4% growth in dietary supplements revenue.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul><h3>Gross Profit Margin</h3><ul><li>Gross profit margin improved to 71.8% from 70.3% in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul><h3>Operating Income</h3><ul><li>Operating income decreased by 32.1% to $8.3 million due to reduced gross profit and higher operating expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul><h3>Net Income</h3><ul><li>Net income for Q3 2025 was $9.2 million, compared to $12.7 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li><li>Diluted earnings per share attributable to biote Corp. stockholders was $0.22, compared to $0.33 in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul><h3>Adjusted EBITDA</h3><ul><li>Adjusted EBITDA was $12.9 million, a decrease of 20.5% from $16.2 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li><li>Adjusted EBITDA margin was 26.9%, down from 31.5% in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash provided by operating activities for the nine months ended September 30, 2025, was $27.6 million, compared to $32.9 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li><li>Net cash used in investing activities for the nine months ended September 30, 2025, was - $4.5 million, compared to - $17.5 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li><li>Net cash used in financing activities for the nine months ended September 30, 2025, was - $34.4 million, compared to - $66.1 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Repurchased approximately one million shares of Class A common stock in Q3 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li><li>Amended settlement agreements with Marci Donovitz and Dr. Gary Donovitz to repurchase their remaining shares at a savings compared to the original agreements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Biote reiterates its 2025 financial outlook, forecasting revenue above $190 million and Adjusted EBITDA above $50 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li><li>2025 procedure revenue is expected to decrease at a high single-digit percentage rate from 2024, while dietary supplements revenue is expected to grow at a mid-teens percentage rate from 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1819253/000119312525266910/btmd-ex99_1.htm"></span></li></ul>

biote Corp. | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 47.96 M